Copyright
©The Author(s) 2020.
World J Clin Cases. Sep 6, 2020; 8(17): 3679-3690
Published online Sep 6, 2020. doi: 10.12998/wjcc.v8.i17.3679
Published online Sep 6, 2020. doi: 10.12998/wjcc.v8.i17.3679
Variables | Global population | Patients non investigated | Patients investigated | P value |
n (%) or mean ± SD | n (%) or mean ± SD | n (%) or mean ± SD | ||
n = 134 | n = 86 | n = 48 | ||
Age (yr) | 61.3 (12.8) | 61.0 (12.1) | 61.9 (14.1) | 0.69 |
Gender (male) | 84 (62.7) | 56 (65.1) | 28 (58.3) | 0.43 |
18FDG PET/CT indications | 0.42 | |||
Diagnosis | 20 (14.9) | 10 (11.6) | 10 (20.8) | |
Follow-up of a known cancer | 47 (35.1) | 32 (37.2) | 15 (31.3) | |
Staging of a known cancer | 45 (33.6) | 32 (37.2) | 13 (27.1) | |
Suspicion of cancer recurrence | 17 (12.7) | 9 (10.5) | 8 (16.7) | |
Diagnosis of infectious/inflammatory disease | 5 (3.7) | 3 (3.5) | 2 (4.2) | |
Primitive cancer | 0.13 | |||
Hematological cancer | 22 (16.4) | 17 (20.0) | 5 (10.5) | |
Head and neck cancer | 14 (10.4) | 9 (10.5) | 5 (10.4) | |
Lung cancer | 25 (18.6) | 21 (24.4) | 4 (8.3) | |
Gynecological cancer | 22 (16.4) | 13 (15.1) | 9 (18.8) | |
Urological cancer | 4 (3.0) | 1 (1.1) | 3 (6.3) | |
Digestive cancer | 14 (10.5) | 8 (3.5) | 6 (12.5) | |
Melanoma | 9 (6.7) | 5 (5.8) | 4 (8.3) | |
Others1 | 7 (5.2) | 3 (3.5) | 4 (8.3) | |
Past history of pelvic radiotherapy2 | 13 (9.7) | 8 (9.3) | 5 (10.4) | 0.83 |
Past history of proctologic diseaseb | 21 (15.7) | 6 (7.0) | 15 (31.3) | 0.0002 |
18FDG PET/CT | ||||
SUV mean | 5.5 (2.3) | 5.3 (2.1) | 5.9 (2.6) | 0.15 |
SUV max | 9.6 (3.9) | 9.2 (3.5) | 10.2 (4.5) | 0.13 |
MV50 (cm3) | 4.1 (2.8) | 4.2 (3.0) | 4.0 (2.3) | 0.65 |
MV41 (cm3) | 6.6 (4.2) | 6.7 (4.6) | 6.4 (3.5) | 0.64 |
MV 30 (cm3) | 11.9 (7.1) | 12.2 (7.7) | 11.4 (5.9) | 0.51 |
All | No treatment offered | Treatment offered | P value | |
n (%) or mean ± SD | n (%) or mean ± SD | n (%) or mean ± SD | ||
n = 48 | n = 30 | n = 18 | ||
Assessmenta by | 0.0457 | |||
Proctologist | 30 (62.5) | 15 (50.0) | 15 (83.3) | |
Gastroenterologist | 10 (20.8) | 7 (23.3) | 3 (16.7) | |
Oncologist | 2 (4.2) | 2 (6.7) | ||
Radiotherapist | 5 (10.4) | 5 (16.7) | ||
Surgeon | 1 (2.1) | 1 (3.3) | ||
Examination | ||||
Anal margin | 46 (95.8) | 29 (96.7) | 17 (94.4) | 0.71 |
Rectal digital examination | 40 (85.2) | 25 (86.2) | 15 (83.3) | 0.78 |
Anoscopy | 24 (51.1) | 12 (41.4) | 12 (66.7) | 0.09 |
Colonoscopy | 17 (36.2) | 11 (38.0) | 6 (33.3) | 0.75 |
Examination under general anesthesiaa | 5 (10.6) | 1 (3.5) | 4 (22.2) | 0.04 |
Biopsies | 8 (17.0) | 3 (10.3) | 5 (27.8) | 0.12 |
Endoanal ultrasound | 7 (14.9) | 5 (17.2) | 2 (11.1) | 0.56 |
Pelvic MRI | 2 (4.3) | 1 (3.5) | 1 (5.6) | 0.73 |
Symptom | 19 (40.4) | 9 (31.0) | 10 (58.8) | 0.06 |
18FDG PET/CT | ||||
SUV meana | 5.9 (2.6) | 5.2 (1.9) | 7.2 (3.2) | 0.02 |
SUV maxa | 10.2 (4.5) | 9.0 (3.3) | 12.4 (5.4) | 0.02 |
MV50 | 4.0 (2.3) | 4.4 (2.4) | 3.3 (2.0) | 0.13 |
MV41 | 6.4 (3.5) | 7.2 (3.6) | 5.1 (3.0) | 0.05 |
MV 30a | 11.4 (6.0) | 12.9 (6.3) | 8.9 (4.4) | 0.03 |
Diagnosis of a proctological diseaseb | 33 (68.8) | 15 (50.0) | 18 (100.0) | 0.003 |
Haemorrhoidal disease | 19 | 2 | 12 | |
Anal fissure | 6 | 1 | 5 | |
Recurrence of rectal adenocarcinoma | 2 | 0 | 2 | |
Condyloma | 3 | 1 | 2 | |
Fecal impaction | 1 | 1 | 0 | |
Anal suppuration | 1 | 0 | 1 | |
Solitary rectal ulcer syndrome | 1 | 0 | 1 | |
Treatment | 18 (37.5) | 18 (100) | ||
Medical treatment | 11 (61.1) | |||
Surgical treatment | 5 (27.8) | |||
Medical and instrumental treatments | 1 (5.6) | |||
Endoscopic treatment | 1 (5.6) |
n (%) | |
Total | 18 (100) |
Medical treatment | 11 (61.1) |
Transit regulator | 4 (22.2) |
Oral analgesic treatment | 1 (5.6) |
Topical treatment | 8 (44.4) |
Treatment of hemorrhoids | 4 (22.2) |
5-aminosalicylic acid | 1 (5.6) |
Antibiotic (metronidazole) | 1 (5.6) |
Botulinum toxin injection | 1 (5.6) |
Healing cream | 1 (5.6) |
Surgical treatment | 5 (27.9) |
Electrocoagulation of condyloma | 1 (5.6) |
Surgery of hemorrhoids | 2 (11.1) |
Fissurectomy | 1 (5.6) |
Posterior pelvectomy | 1 (5.6) |
Instrumental and medical treatment | |
Infrared coagulation and imiquimod | 1 (5.6) |
Endoscopic treatment | |
Hydraulic dilatation | 1 (5.6) |
- Citation: Moussaddaq AS, Brochard C, Palard-Novello X, Garin E, Wallenhorst T, Le Balc’h E, Merlini L’heritier A, Grainville T, Siproudhis L, Lièvre A. Incidental anal 18fluorodeoxyglucose uptake: Should we further examine the patient? World J Clin Cases 2020; 8(17): 3679-3690
- URL: https://www.wjgnet.com/2307-8960/full/v8/i17/3679.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i17.3679